Fig. 6: SIRT1 ISGylation limits tumor responses to doxorubicin. | Experimental & Molecular Medicine

Fig. 6: SIRT1 ISGylation limits tumor responses to doxorubicin.

From: SIRT1 ISGylation accelerates tumor progression by unleashing SIRT1 from the inactive state to promote its deacetylase activity

Fig. 6: SIRT1 ISGylation limits tumor responses to doxorubicin.

a, b SIRT1 KO cells and SIRT1 KO cells complemented with SIRT1 WT or SIRT1 KR were injected into BALB/c nude mice, and the mice were monitored weekly for tumor growth. The animals were subjected to doxorubicin treatment 4 days after injection, as described in the Methods section. The mice were sacrificed, and tumors were harvested (a). The bars indicate the means ± SEMs. n = 6 mice per treatment group (b). c Tumors formed as described in (a) were lysed and subjected to IP with an anti-SIRT1 or anti-ISG15 antibody followed by WB with an anti-ISG15 or anti-SIRT1 antibody, respectively. The lysates were also directly probed with the indicated antibodies.

Back to article page